Tilorone hydrochloride demonstrates potent inhibition of the second phase of platelet aggregation both in vitro and in a rat model.
Answers are grounded in this paper and cite their sources.
Does not support clinical use; leaves open translation of tilorone's platelet effects to human trials.
Tilorone hydrochloride was tested in vitro for inhibition of platelet aggregation in the ADP, collagen, and epinephrine-induced platelet aggregation systems. Tilorone did not significantly inhibit the first phase of platelet aggregation induced by ADP, but was a very potent inhibitor of the second phase of platelet aggregation (release reaction) as illustrated by the epinephrine-induced system. When the compound was given to rats by stomach tube at 100 mg/kg for 2 doses, 24 h apart and blood taken 24 h after the second dose, an inhibition of collagen-induced platelet aggregation was found. This result is interpreted as inhibiting the release reaction and second phase platelet aggregation.
No takes yet. Share an insight, caveat, or question.
MacKenzie et al. (1975) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: